计算溶液所需的质量、体积或浓度。
Zilucoplan，三氟乙酸盐 , 补体 C5 抑制剂
有货
为什么选择此级别
BioReagent 级 提供 ≥98%(HPLC) 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
避光,-20°C储存,干燥,避免反复冻融。超低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Zilucoplan TFA is a 15-amino acid synthetic macrocyclic peptide and a potent inhibitor of complement component 5 (C5), that blocks the cleavage of complement C5 into C5a and C5b which occurs as a consequence of activation of the classical, alternative, or lectin pathways. This mechanism of action inhibits formation of the membrane attack complex (MAC). Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .
Formula: C₁₇₂H₂₇₈N₂₄O₅₅·xC₂HF₃O₂
Summary of Clinical Use
Zilucoplan was progressed to clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). Click here to link to ClinicalTrials.gov's full list of zilucoplan trials. The earliest approval for gMG was issued in Japan in September 2023, with FDA approval following in October, and EMA authorisation in December. In response to the SARS-CoV-2 pandemic plans were made to evaluate zilucoplan in COVID-19 patients, as part of the UK's Accelerating COVID-19 Research and Development (ACCORD) initiative (June 2020). ACCORD aims to fast-track potential treatments for COVID-19 through early-stage clinical trials. The first candidate agents included in the ACCORD study were 10478, MEDI3506 (tozorakimab, and anti-IL33 mAb), acalabrutinib, zilucoplan and nebulised heparin. Through this study researchers would aim to determine if the anti-inflammatory action mediated by zilucoplan has efficacy to reduce mortality in patients with severe COVID-19. In October 2023 the FDA approved zilucoplan to treat gMG in patients with acetylcholine receptor autoantibodies.
Immunopharmacology Comments
Zilucoplan is a terminal complement inhibitor that has demonstrated promising clinical efficacy in patients with autoimmune myasthenia gravis. The functional effect of zilucoplan (i.e. inhibition of membrane attack complex formation) is comparable with the effect of the anti-C5 monoclonal eculizumab that is an approved PNH and generalized myasthenia gravis therapeutic.
规格
产品名称
Zilucoplan，三氟乙酸盐 , 补体 C5 抑制剂
别名
齐卢科普兰 | 齐卢考普兰三氟乙酸盐
英文别名
YG391PK0CC | GTPL10404 | Zilucoplan [USAN] | DTXSID301336930 | Zilucoplan [USAN:INN] | 1841136-73-9 | WHO 10602 | Zilucoplan [INN] | UNII-YG391PK0CC | ZILUCOPLAN [WHO-DD] | Zilucoplan | RA101495 | RA101495 | RA3193 | DB15636
规格或纯度
BioReagent,≥98%(HPLC)
预测分子量
3562.2 (free base)
作用类型
抑制剂
作用机制
补体 C5 抑制剂
CAS编号和信息
1841136-73-9 (free base)
分子类型
肽
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存条件
避光,-20°C储存,干燥,避免反复冻融
运输条件
超低温运输
稳定性与储存
长期储存-20℃（24个月）；避免反复冻融；避光；密封。
技术文档
高级数据
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 ZJ26F0535499 |
分析证书 | rp175435 |
技术文档和文章
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）